Pfizer Expects Zeldox Labeling Negotiations To Continue Past September
Executive Summary
Pfizer expects an "approvable" action from FDA in September to set up a final round of negotiations over labeling for the antipsychotic Zeldox, Pfizer Global R&D President John Niblack indicated during a July 27 investor conference call.
You may also be interested in...
Organon Antidepressant Ariza Expected In 2002 When Remeron Generics Enter
Organon plans to continue its U.S. antidepressant franchise with the 5HT1A partial agonist Ariza.
Organon Antidepressant Ariza Expected In 2002 When Remeron Generics Enter
Organon plans to continue its U.S. antidepressant franchise with the 5HT1A partial agonist Ariza.
Pfizer Zeldox Prolongs QT Interval 30 To 60 Msec In 11.6% Of Patients
The oral formulation of Pfizer's Zeldox is associated with a QT prolongation of 30 to 60 milliseconds in 11.6% of patients, an update of Swedish labeling for the atypical antipsychotic states.